)
Shares of AstraZencea Pharma India have moved higher by 16% to Rs 1,274, extending its past four day’s over 20% rally on the BSE, on back of heavy volumes.
The stock opened at Rs 1,098 and touched a 52-week high of Rs 1,279 on the BSE so far. Till 1502 hours, about 181,398 shares changed hands against an average 31,000 shares that were traded daily in past two weeks on the BSE.
In past one-week the stock of pharmaceutical company has surged 41% from Rs 903 on June 8, compared to a marginal 0.37% rise in the S&P BSE Sensex.
On June 11, the company announced the launch of Forxiga (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus, in the country.
Forxiga belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2).
AstraZeneca Pharma Managing Director Sanjay Murdeshwar said the drug would offer an additional treatment option to over 63 million diabetes mellitus patients in India.
"Forxiga represents a significant advancement in the treatment of Type 2 diabetes mellitus with global safety and efficacy data of four years," he said.
The stock opened at Rs 1,098 and touched a 52-week high of Rs 1,279 on the BSE so far. Till 1502 hours, about 181,398 shares changed hands against an average 31,000 shares that were traded daily in past two weeks on the BSE.
In past one-week the stock of pharmaceutical company has surged 41% from Rs 903 on June 8, compared to a marginal 0.37% rise in the S&P BSE Sensex.
On June 11, the company announced the launch of Forxiga (dapaglifozin), a breakthrough treatment for Type 2 diabetes mellitus, in the country.
Forxiga belongs to a new class of Type 2 diabetes mellitus medication-a highly selective inhibitor of sodium-glucose cotransporter 2 (SGLT2).
AstraZeneca Pharma Managing Director Sanjay Murdeshwar said the drug would offer an additional treatment option to over 63 million diabetes mellitus patients in India.
"Forxiga represents a significant advancement in the treatment of Type 2 diabetes mellitus with global safety and efficacy data of four years," he said.
